Recent 8-K filings for PSNL

• May 20, 2026, 4:04 PM ET regulatory materiality 0.60 positive item 8.01

  CMS expands Medicare coverage for Personalis's NeXT Personal test to monitor neoadjuvant therapy in breast cancer

  New coverage applies to monitoring treatment response to neoadjuvant therapy in Stage II-III TNBC or HER2+ breast cancer patients.

• May 13, 2026, 4:52 PM ET other material materiality 0.15 neutral item 5.07

  Personalis stockholders elect directors, ratify auditor, approve exec compensation at 2026 annual meeting

  Olivia K. Bloom and Woodrow A. Myers, Jr., M.D. elected as Class I directors for three-year terms.

• May 13, 2026, 4:03 PM ET regulatory materiality 0.50 positive item 8.01

  CMS expands Medicare coverage for Personalis' NeXT Personal test to immunotherapy monitoring

  CMS coverage now includes immunotherapy monitoring for late-stage solid tumor patients as of May 12, 2026.

• May 7, 2026, 7:59 PM ET earnings materiality 0.78 positive item 2.02item 9.01 ◈ Earnings Releases

  Personalis Q1 clinical test volume +258% YoY to 7,815; secures Medicare coverage for lung cancer

  Revenue $15.5M vs $20.6M YoY; clinical revenue $1.4M vs $0.3M as non-core revenue declined.

• March 17, 2026, 7:59 PM ET leadership materiality 0.50 neutral item 5.02

  Personalis appoints Richard Chen as President; CEO Hall steps down from President role

  Richard Chen appointed President effective March 13, 2026; he retains EVP R&D and CMO roles.

• February 26, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Personalis reports 400% clinical test volume growth in 2025, guides $78-80M FY2026 revenue

  Clinical volume surged 400% YoY to 16,233 tests; Q4 sequential growth 41% to 6,183 tests.

• January 8, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Personalis Q4 clinical test volume up 41% QoQ; Medicare coverage secured for breast cancer

  Preliminary Q4 2025 revenue $17-18M; full year revenue $69-70M (2024: $84.6M).

• November 28, 2025, 6:59 PM ET other material materiality 0.75 neutral item 8.01item 9.01

  Personalis files prospectus supplement for up to $100M at-the-market stock offering

  Up to $100 million of common stock may be sold under amended ATM sales agreement with Piper Sandler and BTIG.

• November 25, 2025, 6:59 PM ET regulatory materiality 0.90 positive item 8.01

  Personalis gets CMS revised reimbursement rates for NeXT Personal breast cancer test

  CMS revised reimbursement for Personalis' NeXT Personal Dx Breast MRD test to $4,266 effective Dec 1, 2025

• November 10, 2025, 6:59 PM ET regulatory materiality 0.80 positive item 8.01

  Personalis receives Medicare coverage for NeXT Personal in breast cancer MRD surveillance

  CMS covers NeXT Personal Dx Breast MRD test for post-treatment surveillance of stage II/III breast cancer recurrence.

• November 4, 2025, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Personalis Q3 revenue down 44% to $14.5M; clinical tests up 364% YoY; FY guidance reduced

  Revenue $14.5M (-44% YoY); net loss $21.7M ($0.24/sh) vs $39.1M ($0.64) in Q3 2024, prior year included $26M warrant expense.

• August 22, 2025, 7:59 PM ET other material materiality 0.60 positive item 8.01

  Personalis receives $13.5M new task order under VA Million Veteran Program contract

  New task order effective Sept 30, 2025, valued up to $13.5M subject to sample receipt and service performance.

• August 5, 2025, 7:59 PM ET earnings materiality 0.80 negative item 2.02item 9.01

  Personalis Reports Q2 2025 Revenue of $17.2M, Net Loss $20.1M; Clinical Test Volume Up 59% Sequentially

  Delivered 3,478 clinical tests in Q2 2025, a 59% sequential increase over Q1 2025.

• July 9, 2025, 7:59 PM ET other material materiality 0.60 positive item 1.01

  Personalis expands Tempus partnership to colorectal cancer MRD; term to 2029

  Tempus authorized to market NeXT Personal MRD test for colorectal cancer, fourth indication.

• May 19, 2025, 7:59 PM ET other material materiality 0.15 neutral item 5.07

  Personalis annual meeting: directors elected, auditor ratified, say-on-pay passes

  A. Blaine Bowman elected as Class III director with 58.2M for, 710K withheld; Karin Eastham with 53.7M for, 5.2M withheld.

• May 6, 2025, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01

  Personalis Q1 revenue $20.6M (+6% YoY); clinical test volume up 52% sequentially

  Revenue $20.6M, up 6% YoY; pharma tests/services $13.6M (+39%), population sequencing $6.7M (-29%).

• February 27, 2025, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Personalis reports FY24 revenue $84.6M (+15% YoY); provides FY25 guidance with $80-90M revenue, net loss ~$85M

  FY24 revenue $84.6M (+15% YoY); net loss $81.3M vs $108.3M in FY23; cash $185M including $50M Merck investment.

• January 7, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Personalis reports FY2024 revenue ~$84.6M (+15% YoY), above guidance; cash ~$185M

  Full year 2024 revenue of ~$84.6M, up 15% from $73.5M in 2023, above guidance range of $83-84M.

• December 27, 2024, 6:59 PM ET other material materiality 0.50 neutral item 8.01item 9.01

  Personalis enters amended ATM equity sales agreement with Piper Sandler and BTIG

  Amended and Restated ATM Sales Agreement dated Dec 27, 2024 with Piper Sandler & Co. and BTIG, LLC as sales agents.

• December 19, 2024, 6:59 PM ET other material materiality 0.85 positive item 1.01item 3.02item 8.01item 9.01

  Personalis secures $50M Merck investment, extends Moderna pact, expands Tempus deal

  Merck to purchase 14,044,943 shares at $3.56/share for ~$50M; closing expected Dec 19, 2024.

• November 6, 2024, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Personalis Q3 revenue $25.7M (+41% YoY); raises FY 2024 guidance to $83-84M

  Revenue $25.7M, up 41% YoY; biopharma revenue $15.7M (+96% YoY).

• September 19, 2024, 7:59 PM ET other material materiality 0.65 positive item 8.01

  Personalis receives $7.5M new task order from VA Million Veteran Program; cumulative orders reach $210.7M

  New task order under VA Million Veteran Program contract effective Sept. 30, 2024, valued up to $7.5M.

• August 16, 2024, 7:59 PM ET other material materiality 0.75 positive item 1.01item 3.02item 7.01item 9.01

  Tempus invests $36M in Personalis, exercises warrants and buys shares; expands commercial collaboration

  Tempus exercises warrants for 9.2M shares at avg $2.00 ($18.4M) and buys 3.5M shares at $5.07 ($17.7M).

• August 7, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Personalis Q2 revenue $22.6M (+35% YoY); raises FY 2024 revenue guidance to $79-81M

  Total revenue $22.6M, up 35% YoY; pharma testing $13.2M (+117% YoY).

• June 27, 2024, 7:59 PM ET other material materiality 0.55 neutral item 1.01item 9.01

  Personalis settles patent litigation with Foresight, grants license for MRD tests, receives tiered royalties

  Settled pending infringement claims and IPR proceedings with Foresight Diagnostics.

• May 21, 2024, 7:59 PM ET other materiality 0.10 neutral item 5.07

  Personalis annual meeting: directors elected, auditor ratified, say-on-pay approved

  Christopher Hall, Lonnie Shoff, Kenneth J. Widder elected Class II directors until 2027.

• May 8, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01 ◈ Earnings Releases

  Personalis Q1 revenue $19.5M beats guidance; raises FY24 revenue outlook to $76-78M

  Q1 2024 revenue $19.5M (up 3% YoY), exceeding upper-end of guidance; pharma testing revenue grew 55% to $9.8M.

• February 28, 2024, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases ×2

  Personalis Q4 revenue $19.7M (+18% YoY); FY2024 revenue guidance $73-75M

  Q4 2023 revenue $19.7M (+18% YoY); FY2023 revenue $73.5M (+13% YoY).

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.72 · Most common event earnings

17 positive 1 negative 10 neutral

source · PSNL on sec.gov